???global.info.a_carregar???
Fábio Fiúza Rosa, PhD, is Head of Research and co-founder of Asgard Therapeutics. With a double PhD in Experimental Biology and Biomedicine by the University of Coimbra (Portugal) and Lund University (Sweden), Fábio pioneered the use of cell reprogramming to induce dendritic cell fate in vivo. Fábio has filed 5 patents and won over 15 awards. He leads R&D activities focused on harnessing dendritic cell reprogramming technologies for cancer immunotherapy. Fabio’s ambition is to expand the reach of dendritic cell reprogramming to develop novel immunotherapies for the benefit of patients with solid tumors.
Read full resume ↓
Identification

Personal identification

Full name
Fábio Alexandre Fiúza Rosa

Citation names

  • Rosa, Fábio
  • Rosa F. F.

Author identifiers

Ciência ID
7015-18A9-714C
ORCID iD
0000-0002-7714-5852

Websites

Knowledge fields

  • Medical and Health Sciences - Basic Medicine - Immunology

Languages

Language Speaking Reading Writing Listening Peer-review
English Intermediate (B1) Intermediate (B1) Intermediate (B1) Intermediate (B1)
Portuguese Advanced (C1) Advanced (C1) Advanced (C1) Advanced (C1)
Education
Degree Classification
2018/01/01 - 2021
Concluded
 Doutoramento em Biologia Experimental e Biomedicina (Doutoramento)
Major in Immunology
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2016
Concluded
 Mestrado em Bioquímica (Mestrado)
Universidade de Coimbra Faculdade de Ciencias e Tecnologia, Portugal
"Direct Reprogramming of fibroblasts to Dendritic Cells for immunotherapy" (THESIS/DISSERTATION)
 18
2014
Concluded
 Licenciatura em Biologia (Licenciatura)
Universidade de Coimbra Faculdade de Ciencias e Tecnologia, Portugal
"n/a" (THESIS/DISSERTATION)
 14
Affiliation

Science

Category
Host institution 		Employer
2021 - Current Principal Investigator (Research) Asgard Therapeutics, Sweden
2018/01/01 - 2021 Researcher (Research) Universidade de Coimbra Instituto de Investigação Interdisciplinar, Portugal
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Others

Category
Host institution 		Employer
2015/08/22 - 2016/09/19 Master's student (Biochemistry) under supervision of Dr. Carlos Filipe Pereira. Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Projects

Grant

Designation Funders
2025 - Current REPRO-TILs: Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell Reprogramming
101213733
Principal investigator
European Innovation Council
Ongoing
2024 - Current RESYNC: Functional chemical reprogramming of cancer cells to induce antitumor immunity
101130218
Co-Principal Investigator (Co-PI)
European Innovation Council
Ongoing
2021 - Current REPRogramming tumors INTo immune cells: a revolutionary gene therapy to treat cancer (REPRINT)
E!115376
Core Team Member
Horizon 2020
2021 - Current Support Turning head and neck cancer into immune cells: preclinical validation and clinical plan of TrojanDC
1
Core team member
Vinnova
2021 - Current Develop an intangible asset strategy for Smile Incubator companies
1
Core team member
Vinnova
2020 - Current TrojanDC – Turning Tumors into Immune Cells: A Revolutionary Gene Therapy to Treat Cancer
1
Core team member
Lunds Universitet
2020 - Current Developing a new cancer immunotherapy based on dendritic cell reprogramming
1
Other
Novo Nordisk Denmark A/S
2019 - Current Lund University Innovation VFT Funds
1
Core team member
2019 - Current Horizon 2020 SME instrument Phase 1 Grant
TrojanDC
Core team member
2019 - Current Novo Nordisk Exploratory Pre-Seed Grant
Novo Nordisk
Core team member
2020 - 2020 Vinnova Innovative Startups Step 2
1
Core team member
Vinnova
2019 - 2019 IPA4SME support for intellectual property (IP) valorisation and protection
COSME
Core team member
2019 - 2019 Sten K Johnson Stiftelse grant
Sten K Johnson Stiftelse
Core team member
2019 - 2019 Lund University Innovation IKS Accelerator grant 2019
Innovation IKS Accelerator
Core team member
2019 - 2019 Lund University Innovation VFT Funds
Innovation VFT
Core team member
2018 - 2018 Vinnova Innovative Startups to support Regulatory and IP strategy
Vinnova Innovative Startups
Other
2018 - 2018 StemTherapy Lund Innovation award
StemTherapy Lund Innovation
Core team member
2017 - 2017 Centro2020 Project to protect intellectual property
WO-2018-185709-A1
Core team member
2017 - 2017 Entrepreneurship competition Montepio Acredita Portugal Health Prize
Montepio Acredita
Other
2016 - 2016 Business Plan Competition Arrisca C
Arrisca C
Core team member
Outputs

Publications

Journal article
  1. Ascic, Ervin; Åkerström, Fritiof; Sreekumar Nair, Malavika; Rosa, André; Kurochkin, Ilia; Zimmermannova, Olga; Catena, Xavier; et al. Corresponding author: Rosa F. F.. "In vivo dendritic cell reprogramming for cancer immunotherapy". Science 386 6719 (2024): https://doi.org/10.1126/science.adn9083.
    10.1126/science.adn9083
  2. Zimmermannova, Olga; Ferreira, Alexandra G.; Ascic, Ervin; Velasco Santiago, Marta; Kurochkin, Ilia; Hansen, Morten; Met, Özcan; et al. "Restoring tumor immunogenicity with dendritic cell reprogramming". Science Immunology 8 85 (2023): https://doi.org/10.1126/sciimmunol.add4817.
    10.1126/sciimmunol.add4817
  3. Rosa F. F.; Pires, Cristiana F.; Kurochkin, Ilia; Halitzki, Evelyn; Zahan, Tasnim; Arh, Nejc; Zimmermannová, Olga; et al. "Single-cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells". Science Immunology 7 69 (2022): https://doi.org/10.1126/sciimmunol.abg5539.
    10.1126/sciimmunol.abg5539
  4. Rosa F. F.; Pires, Cristiana; Zimmermannova, Olga; Pereira, Carlos-Filipe. Corresponding author: Pereira, Carlos-Filipe. "Direct Reprogramming of Mouse Embryonic Fibroblasts to Conventional Type 1 Dendritic Cells by Enforced Expression of Transcription Factors". BIO-PROTOCOL 10 10 (2020): https://doi.org/10.21769/bioprotoc.3619.
    10.21769/bioprotoc.3619
  5. Pires, Cristiana F.; Rosa, Fábio F.; Kurochkin, Ilia; Pereira, Carlos-Filipe. "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology 10 (2019): http://dx.doi.org/10.3389/fimmu.2019.02809.
    10.3389/fimmu.2019.02809
  6. Pires, Cristiana F.; Rosa F. F.; Kurochkin, Ilia; Pereira, Carlos-Filipe. "Understanding and Modulating Immunity With Cell Reprogramming". Frontiers in Immunology 10 (2019): https://doi.org/10.3389/fimmu.2019.02809.
    10.3389/fimmu.2019.02809
  7. Rosa F. F.; Pires, Cristiana F.; Kurochkin, Ilia; Ferreira, Alexandra G.; Gomes, Andreia M.; Palma, Luís G.; Shaiv, Kritika; et al. "Direct reprogramming of fibroblasts into antigen-presenting dendritic cells". Science Immunology 3 30 (2018): https://doi.org/10.1126/sciimmunol.aau4292.
    10.1126/sciimmunol.aau4292
  8. Fábio F. Rosa; Cristiana F. Pires; Ilia Kurochkin; Alexandra G. Ferreira; Andreia M. Gomes; Luís G. Palma; Kritika Shaiv; et al. "Direct reprogramming of fibroblasts into antigen-presenting dendritic cells". Science Immunology 3 30 (2018): eaau4292-eaau4292. https://doi.org/10.1126/sciimmunol.aau4292.
    10.1126/sciimmunol.aau4292
Thesis / Dissertation
  1. Rosa, Fábio Alexandre Fiúza. "Direct Reprogramming of Fibroblasts to Dendritic Cells for Immunotherapy". Master, 2016. http://hdl.handle.net/10316/33773.

Intellectual property

Patent
  1. Nejc Arh, Beatriz Vaz, Fábio Rosa and Filipe Pereira. 2023. "RNA-based strategies for dendritic cell reprogramming and uses thereof".
    Pending
  2. Fábio Rosa, Cristiana Pires and Filipe Pereira. 2023. "Constructs and vectors for reprogramming cells to cDC1 cells, compositions and methods thereof".
    Pending
  3. Carlos-Filipe Pereira, Cristiana Pires, Fábio Rosa. 2021. "Compositions for reprogramming cells into plasmacytoid dendritic cells or interferon producing cells, methods and uses thereof".
  4. Carlos-Filipe Pereira, Cristiana Pires, Fábio Rosa, Luís Oliveira. 2021. "Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof.".
  5. Fábio Rosa, Olga Zimmermannova, Alexandra Ferreira, Ervin ASCIC, Cristiana Pires, Carlos-Filipe Pereira. 2021. "Reprogramming of cells to type 1 conventional dendritic cells or antigen presenting cells".
  6. Carlos-Filipe Pereira, Cristiana Pires, Fábio Rosa. 2017. "Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof".

Other

Spin-off company
  1. 2018. Asgard Therapeutics. Immunotherapy, Cancer.
  2. 2017. BRT Blood Reprogramming Technologies.
Activities

Event participation

Activity description
Type of event 		Event name
Institution / Organization
2023 - 2023 What I wish I would have known: Advice from Alumni
Meeting
 PhD Day
Lunds Universitet, Sweden
2020 - 2020 Ideas Salon: Europe & Americas
Round table
 World Congress of Science and Factual Producers
2020 - 2020 Entrepreneurship at the “What Else: A world of opportunities" What Else: A world of opportunities
2018 - 2018 Pharmaceuticals & Industry: From Research to development
Conference
 IV Bioengineering Week
Distinctions

Award

2024 Under 34 Changemaker Award – Innovation Path
2023 Rapidus & PwC 34 Under 34 Award 2020, 2021, 2022, 2023
2021 The Nova 111 List – Sweden – Healthcare & Life Sciences
2021 The Maja and Hjalmar Leander Foundation Award: Best PhD thesis
2020 Lund University and Sparbanken Skåne’s Honor Award 2020
Lunds Universitet, Sweden
2019 EMBO Travel Grant to attend the EMBO Workshop in Antigen Processing and Presentation
2019 EIT Health PhD Translational Fellowship
EIT Health, Germany
2019 Jury’s Best Pitch Award
EIT Health, Germany
2019 Best Pitch Award
NOME, Denmark
2018 Best poster presentation award
2017 Best oral presentation award
2017 PhD Scholarship (SFRH/BD/130845/2017)

Title

2020 Forbes 30 Under 30 Europe 2020: Science & Healthcare
Forbes, Portugal

Other distinction

2017 1st BEB/Bluepharma Award
2016 Innocentive Challenge in immunology and development of novel immunotherapies (9933820), Second Place Award out of 195 international solvers.
2016 Bolsa de investigação (BIM: PTDC/BIMMED/0075/2014) no Laboratório de reprogramação celular e Hematopoiese, CNC/UC-Biotech, Universidade de Coimbra, Portugal.
Fundação para a Ciência e a Tecnologia, Portugal